Fetrastobart vedotin

维芙曲苏拜单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameFetrastobart vedotin
Drug Alias NameSGN-PDL1VPF-08046054
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionProgrammed death-ligand 1 blockersTubulin polymerisation inhibitors
TargetsProgrammed death-ligand 1Tubulin
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[29] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer (Beijing) Research and Development Co LtdSeagen IncPfizer Inc +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A